Early access
Sign in
Taking peoplePhase 2/3

ELA026 for secondary hemophagocytic lymphohistiocytosis, including cases triggered by lymphoma

Tests ELA026 in people with secondary hemophagocytic lymphohistiocytosis, looking at survival.

Key facts

Who runs it
Electra Therapeutics Inc.
Where
Germany, Italy, Netherlands, and Spain15 sites in 4 countriesChoose a country to see its sites
Registry title
Open-label Study of ELA026 in Participants with sHLH (short title)
Status
Recruiting
Phase
Phase 2/3
People taking part
40 people, planned
Started
19 Sept 2025
Expected to end
25 Mar 2028
Type of study
Interventional
Record updated
4 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with secondary hemophagocytic lymphohistiocytosis (sHLH), an overactive immune reaction set off by another illness. Cohort A is for people not treated before whose HLH is triggered by lymphoma.

Age
The record does not give exact ages. Cohort B includes children, with a first group of 6 to 12 year olds.
Sex
All sexes can join.
Disease stage
Secondary HLH. Daily activity level ECOG 3 or lower. Organs must work well enough to take part.
Earlier treatment
Cohort A: people who have not been treated before for HLH.

Main reasons for not taking part

  • HLH that did not respond to treatment (except the 6 to 12 year old safety group in Cohort B)
  • Known or suspected inherited (primary) HLH
  • Severe organ problems
  • Advanced cancer triggering the HLH with no treatment options left
  • Allergy to dexamethasone or to any part of ELA026

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Age and disease
  • Adequate organ function that in consideration of the underlying disease trigger and HLH would support enrollment in a clinical trial
  • Must be Eastern Cooperative Oncology Group (ECOG) ≤3; 4.Cohort A and Cohort B: Participant or legally authorized representative(s) (LAR) capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol. ICF must be signed prior to initiation of any study related activities unless assessments are conducted as part of routine SOC as indicated in the screening SoA; 5.Cohort B: Minor participants must be capable of giving written assent as appropriate per the applicable age (per local regulatory requirements). Participant or LAR capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol. ICF must be signed prior to initiation of any study related activities

Who cannot take part

  • Any other significant concurrent, uncontrolled medical condition that contraindicates participation in this study or prohibits completion of study procedures
  • Ongoing social, psychological, religious or spiritual beliefs, or logistical issues that would prevent following study procedures or receiving supportive care to receive study treatment safely please see the protocol for whole list
  • End-stage malignancy for which no suitable therapies are available to treat the malignancy triggering the HLH (participants with refractory malignancy with ongoing therapeutic options are not excluded)
  • History of hypersensitivity or allergy to dexamethasone
  • History of hypersensitivity or allergy to any components of ELA026
  • Refractory sHLH (exception is the safety lead-in cohort for 6 to 12 year olds with refractory sHLH in Cohort B)
  • Known or suspected primary or hereditary HLH
  • Severe organ dysfunction (see protocol for the list)

This trial has no sites in United States.

It has sites in 4 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

Cohort A: To determine 56-day survival with ELA026 treatment in participants with mHLH who are TN and have lymphoma as the cancer trigger

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
A Phase 2/3, Open-label, Single-arm, Multicenter, Historical Control Study to Evaluate ELA026 in Participants with Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Plain-language title
ELA026 for secondary hemophagocytic lymphohistiocytosis, including cases triggered by lymphomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
4 November 2026